Lepu Medical

Surgerii Robotics: Single-Port Surgical Robots Poised to Transform Surgery

The worldwide surgical robotic market is expected to grow at a booming CAGR of 5.8% during 2022 to 2030, rising from USD 5.05 billion in 2022 to USD 21.41 billion in 2030. Of which, the single-port surgical robots that result in less pain, fewer scars, and quicker recovery, have tremendous up potential.

HastenPharma Secures USD 315 Mn in Financing to Focus on M&A Business and R&D

Anhui-based biopharmaceutical company HastenPharma(海森生物) raised USD 315 million in funding on April 20, with the financing round aimed at focusing on future mergers and acquisitions and product innovation, according to EqualOcean.

Artificial Cardiac Company CoretechMed Raises Nearly CNY 200 Mn in Series C+

In the past five years, China's ventricular assist technology (i.e., "artificial heart") has developed rapidly, and three domestic implantable ventricular assist devices (LVADs) have been approved and marketed by the State Drug Administration, and another one is in the marketing declaration stage. The number of LVAD implantations has increased yearly, with a total of 363 LVAD implantations performed in 70 hospitals, a rapid increase.

Top 10 Market Cap Chinese Medical Device Companies: Champions and Runners-Up

In a recent boom in the Chinese A-share market, the medical device segment has shown a surprising performance, proving its investability and growth potential.

USD 130 Million Series A Financing Fuels Lepu Biotech

Lepu Biotech announced Series A financing of CNY 900 million. Shiyu Capital took the lead in this round. Lepu Biotech has several pipelines for precision treatment and targeted therapy for solid tumors.